President Trump touring the Bioprocess Innovation Center at Fujifilm Diosynth Biotechnologies, Morrisville, NC (Evan Vucci/AP Images)

Covid-19 roundup: Pe­ter Kolchin­sky’s RA Cap­i­tal spear­heads 'Covid Apol­lo,' a VC search for the best test; Up­start grabs €23M for nanobod­ies

Covid-19 test­ing in the US has been, well, a com­plete mess. Four months in­to the pan­dem­ic, lines for tests in some ar­eas still stretch for miles, test­ing sites run out of spots min­utes af­ter open­ing, and peo­ple of­ten wait more than a week to get re­sults — a thorny bun­dle of de­lays and short­falls that un­der­mines the US’ abil­i­ty to con­tain a bur­geon­ing out­break.

Nu­mer­ous pro­pos­als have been put for­ward to ad­dress the test­ing deficit, most of them around in­creased gov­ern­ment spend­ing. Ear­li­er this month, the Rock­e­feller Foun­da­tion put out a re­port call­ing for $75 bil­lion in pub­lic funds to ramp up the most­ly ac­cu­rate but time-con­sum­ing PCR tests to 5 mil­lion tests per week, and ramp up the rapid but less pre­cise anti­gen test to 30 mil­lion per week.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.